You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 273 No. 20, May 24, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Including Narcotic Addiction Treatment in an Office-Based Practice

James R. Cooper, MD

JAMA. 1995;273(20):1619-1620.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE REGULATION of narcotic medications used in narcotic addiction treatment is unique in medical therapeutics. Physicians who want to administer or dispense opioid drugs for either narcotic maintenance or detoxification treatment by federal law must first obtain an additional annual registration from the Drug Enforcement Administration (DEA). This registration is separate from the registration familiar to physicians who prescribe other controlled medications. The additional registration is contingent on compliance both with the DEA's security regulations (inventory, record keeping, and physical security) as well as with annual certification from the US Department of Health and Human Services (DHHS). DHHS certification is contingent on approval by individual state drug authorities and compliance with treatment regulations jointly promulgated by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse. Authority for this separate registration emanates from the Narcotic Addict Treatment Act (NATA) of 1974,1 which was enacted to give . . . [Full Text PDF of this Article]


Author Affiliations

From the Associate Director for Medical Affairs, Division of Clinical and Services Research, National Institute on Drug Abuse, Rockville, Md.


Footnotes

The views and opinions expressed herein are those of the author and do not necessarily reflect those of the National Institute on Drug Abuse.

Reprint requests to the Associate Director for Medical Affairs, Division of Clinical Services and Research, National Institute on Drug Abuse, 5600 Fishers Ln, Rockville, MD 20857 (Dr Cooper).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.